Desiree Levyim, MD
Neurology with Special Qualifications in Child Neurology · West Hills, CANPI 1497167985
Payments from drug & device makers
Across 245 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$605
- Pfizer$569
- Harmony Biosciences LLC$533
- Novartis$371
- Biohaven Pharmaceutical Holding Company Ltd.$348
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,515100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $1,040 |
| Teva Pharmaceuticals USA, Inc. | 28 | $605 |
| Pfizer | 32 | $569 |
| Harmony Biosciences LLC | 13 | $533 |
| Novartis | 16 | $371 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $348 |
| Eisai Inc. | 8 | $253 |
| Acadia Pharmaceuticals Inc | 9 | $180 |
| Neurelis, Inc. | 7 | $131 |
| Medtronic | 1 | $127 |
| Jazz Pharmaceuticals Inc. | 4 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $119 |
| SK Life Science, Inc. | 1 | $118 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Sumitomo Pharma America, Inc. | 11 | $91 |
| Aucta Pharmaceuticals, Inc. | 5 | $90 |
| Biogen | 5 | $89 |
| UCB, Inc. | 3 | $76 |
| MDD US Operations, LLC | 1 | $73 |
| Lundbeck LLC | 3 | $66 |
| Mallinckrodt Enterprises LLC | 2 | $64 |
| Argenx US, Inc. | 2 | $55 |
| EMD Serono, Inc. | 1 | $51 |
| Biohaven Pharmaceuticals, Inc. | 2 | $46 |
| Amgen | 2 | $43 |
| Lilly USA, LLC | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $27 |
| Abbott | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Forte Bio-pharma LLC | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wakix$241
- PERCEPT PC BRAINSENSE$127
- DUPIXENT$119
- Leqembi$115
How this compares
$5,529 in reported general payments places this provider in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 49 | $73,260 |
| QuliptaAtogepant | 29 | $30,761 |
| RexultiBrexpiprazole | 17 | $24,601 |
| RytaryCarbidopa/Levodopa | 13 | $4,567 |
| Memantine Hcl ErMemantine Hcl | 42 | $3,998 |
| Memantine Hcl | 105 | $3,463 |
| Gabapentin | 161 | $2,189 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 58 | $1,388 |
| Lidocaine | 18 | $1,375 |
| Pregabalin | 74 | $1,264 |
| Donepezil Hcl | 98 | $1,252 |
| Entacapone | 12 | $1,177 |
| Levetiracetam | 46 | $1,072 |
| Quetiapine Fumarate | 53 | $950 |
| Primidone | 68 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $569 | $73,26049 claims |
| AbbVieQulipta | $1,040 | $30,76129 claims |
| Amneal Pharmaceuticals LLCRytary | $24 | $4,56713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in West Hills
- Sabine MuellerSan Francisco$17.5M
- Joseph SullivanSan Francisco$1.7M
- Rajsekar RajaramanLos Angeles$1.5M
- Jonathan SantoroPalo Alto$1.5M
- Michelle MonjePalo Alto$1.3M
- Jay DesaiLos Angeles$1.2M
- Richard HaasSan Diego$1.2M
- Leigh Maria Ramos PlattLos Angeles$981K
- Agnes ChenTorrance$792K
- Wendy MitchellLos Angeles$749K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.